Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Leases: 2015-2018

Historic Capital Leases for Seres Therapeutics (MCRB) over the last 3 years, with Dec 2018 value amounting to $6.8 million.

  • Seres Therapeutics' Capital Leases fell 24.62% to $6.8 million in Q4 2018 from the same period last year, while for Dec 2018 it was $6.8 million, marking a year-over-year decrease of 24.62%. This contributed to the annual value of $6.8 million for FY2018, which is 24.62% down from last year.
  • According to the latest figures from Q4 2018, Seres Therapeutics' Capital Leases is $6.8 million, which was down 11.83% from $7.7 million recorded in Q3 2018.
  • Over the past 5 years, Seres Therapeutics' Capital Leases peaked at $10.7 million during Q3 2016, and registered a low of $586,000 during Q4 2015.
  • Its 3-year average for Capital Leases is $8.7 million, with a median of $9.1 million in 2016.
  • Its Capital Leases has fluctuated over the past 5 years, first soared by 1,731.06% in 2016, then dropped by 24.62% in 2018.
  • Seres Therapeutics' Capital Leases (Quarterly) stood at $586,000 in 2015, then soared by 1,731.06% to $10.7 million in 2016, then declined by 16.23% to $9.0 million in 2017, then dropped by 24.62% to $6.8 million in 2018.
  • Its Capital Leases was $6.8 million in Q4 2018, compared to $7.7 million in Q3 2018 and $8.1 million in Q2 2018.